Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Maintenance After Autologous HSCT in Primary CNS Lymphoma
ChiCTR2000035939Phase 2Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Aug 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in primary central nervous system lymphoma (PCNSL), sponsored by Huashan Hospital. Primary endpoints: Progression-free survival and Relapse rate. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2000035939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035939.